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Ovarian carcinoma is the most lethal disease among
all gynecological malignancies. The World Health Or-
ganization has classified ovarian tumors into some
According to the origin of the cells, WHO categorized
ovarian tumors as germ cells tumors, sex-cord tumors,
stromal tumors and surface epithelial tumors. Ovarian
tumors can also be classified as benign, low potential
malignant (borderline), or malignant tumors according
to certain criteria which include layer of cells, cellular
proliferation, pleomorphism, and stromal invasion.
Almost 90% of the malignancies are actually surface
epithelial stromal type. Scarce information on initia-
tion and progression are provided. Hereinafter the pa-
thologist will classify epithelial type cancer into serous,
clear cell, endometrioid, mucinous and other sub-
types.1-3
Abstrak
Tujuan: Artikel ini bertujuan untuk membahas mengenai dua
jalur patogenesis kanker ovarium dan implikasinya terhadap mana-
jemen kanker ovarium.
Metode: Tinjauan pustaka
Hasil: Patogenesis kanker ovarium dapat dibagi menjadi tipe I
dan tipe II berdasarkan penelitian-penelitan patologi anatomi dan
molekular genetik. Kanker ovarium dengan subtipe low-grade serous,
mucinous, clear cell, dan endometrioid. dikategorikan memiliki pola
pertumbuhan kanker tipe I. Tipe I ini cenderung untuk berkembang
perlahan, menunjukkan respons yang kurang baik pada kemoterapi
platinum dan sebagian besar menunjukkan mutasi pada jalur
MAPK. Kanker ovarium subtype high-grade serous biasanya ber-
kembang lebih cepat dan agresif dan mengakibatkan buruknya prog-
nosis pasien. Kanker ovarium jenis ini kemudian dikategorikan
memiliki pola pertumbuhan kanker tipe II. Kanker tipe II ini banyak
ditemukan mengalami mutasi pada gen TP53. Operasi yang optimal
sebelum kemoterapi merupakan manajemen pilihan untuk kedua
tipe tersebut sampai saat ini. Walaupun demikian, sitoreduksi opti-
mal sangat ditekankan pada tipe II untuk meningkatkan angka over-
all survival dan disease-free interval. Skrining lesi minimal dengan
biomarker untuk kanker ovarium tipe II menjadi sangat penting
mengingat insepsi awalnya sangat sulit untuk dideteksi. Sementara
itu skrining BRCA1/2 disertai perkembangan informasi terhadap
klasifikasinya dibutuhkan sebagai metoda skrining untuk pasien-
pasien dengan sindroma kanker payudara-ovarium herediter. Mutasi
pada KRAS, BRAF, PTEN dan CTNNB1 terutama didapatkan pada
kanker ovarium tipe I sehingga penelitan terhadap terapi inhibitor
dan kemoterapi dengan target tertentu yang biasanya ditujukan
kepada kanker ovarium tipe II rekuren dapat juga diarahkan pada
kanker tipe I yang memiliki respons rendah terhadap kemoterapi
platinum.
Kesimpulan: Strategi untuk skrining, pendekatan awal dan
kemoterapi terhadap kanker ovarium dapat dikembangkan ber-
dasarkan dua jalur tumor genesis terbaru yang memiliki pola yang
berbeda.
[Maj Obstet Ginekol Indones 2009;33-4:239-46]
Kata kunci: kanker ovarium, karsinogenesis, skrining, sitore-
duksi, kemoterapi
Abstract
Objective: To review the two designated pathways of ovarian
cancer and their implications to the management of ovarian cancer.
Method: Literature review
Result: A proposed carcinogenesis of ovarian cancer has been
developed based on a long history of pathological and molecular
genetic findings. It divides ovarian cancer as having designated type
I or type II pathway. Type I pathway involves ovarian carcinomas
with low-grade serous subtype, mucinous, clear cell and endo-
metrioid subtypes. They grow in a stepwise manner, shows low re-
sponse toward platinum-based chemotherapy and mostly relate to
MAPK pathway mutations. High-grade serous ovarian carcinomas
which are often found in rapid-aggressive progression with poorer
prognosis are suggested as type II pathway. Their major mutations
are mainly in TP53. Optimal surgery and adjuvant chemotherapy
are the treatment for both confined and advanced cancers. How-
ever, the optimal cytoreduction in type II pathway is becoming more
important to increase overall survival or disease-free interval. The
strategy of screening type II pathway is proposed to be shifted from
detection of stage I tumors to detection of minimal ovarian carcino-
mas probably by biomarkers since the rapid inception is hardly
found. Meanwhile the BRCA1/2 screening and classification should
be improved for the hereditary breast/ovarian cancer screening.
Mutations of KRAS, BRAF, PTEN and CTNNB1 occur majorly in
the type I tumors. Therefore, targeted chemotherapy and inhibitor
treatments which are investigated foremost in type II recurrence of
ovarian malignancies may also be directed to the low response of
type I pathway to platinum-based chemotherapy.
Conclusion: A different strategy based on the tumorigenesis of
ovarian cancer should be considered in term of screening, primary
approach and following chemotherapy since there are some distinc-
tive patterns in both pathways.
[Indones J Obstet Gynecol 2009;33-4:239-46]
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The management of epithelial ovarian cancer be-
gins with an optimal surgical staging procedure after
a careful diagnosis. All subtypes of histology findings
will be treated as a single entity of ovarian malig-
nancy. Then, it is followed by the first line chemo-
therapy agents which are almost similar for all early
stages and advanced stages; paclitaxel and carbo-
platin.1 The classification of early stage and advanced
stage are employed to decide the treatment approach.
The chemotherapy administration for ovarian can-
cers stage IA and IB with well-differentiated and
moderately-differentiated tumors which are consid-
ered as early stages remains controversy. Whilst the
rest stages categorized as advanced stages will defi-
nitely require recommended adjuvant chemo-therapy
after surgical management.4 Recent clinicopathologi-
cal and molecular studies propose two different path-
ways of ovarian carcinogenesis which are different in
term of morphology and molecular biology.3,5
Model of Ovarian Tumorigenesis Based on
Morphological and Molecular Genetic Analysis
A rigorous systematic microscopic and clinical analy-
sis involving a large number of invasive and non-
invasive epithelial tumors of all histological types of
ovarian cancer has been conducted for almost 15
years. Despite of categorizing ovarian malignancy
into different kinds of subhistopathological subtypes,
a review toward advanced stage and early stage of
ovarian cancer revealed differences in term of clinical
behavior, morphological and molecular genetic analy-
sis. Most of the early stages of ovarian cancer are
clear cell, endometrioid and mucinous subtypes.
Serous subtypes are majorly found in patients with
advanced stages, only some of them were showed
early growth. The serous type is divided further into
high grade and low grade which follow two contrast-
ing pathways of development.3,6-8 Current molecular
genetic studies along with histopathological and cli-
nical findings suggest that there are two designated
pathways of ovarian tumorigenesis; type I consists of
low-grade ovarian cancers presenting slow progres-
sion, type II consists of high-grade ovarian cancers
with rapid progression.
Type I is more likely to develop in stepwise man-
ner supported by recognized precursors appearance
(Figure 1). The clear cell, endometrioid, mucinous
and low-grade serous carcinoma subtypes belong in
this type. Each subtype shows a precursor state in
pathological findings. Adenofibroma or atypical pro-
liferative serous tumor develop into non invasive mi-
cropapilary serous carcinoma (MPSC) or serous bor-
derline ovarian tumor (SBT) and in turn into invasive
low grade serous carcinoma or invasive MPSC, The
indolent course of MPSC may last for more than 20
years.4,9,10
Atypical proliferative serous tumor or SBT and
MPSC show well-characterized molecular alterations
as sequence mutations of KRAS and BRAF onco-
genes. A study on sporadic serous ovarian malignan-
cies demonstrated that KRAS mutations occurred in
approximately 50% of SBT, MPSC, and invasive
MPSC.11 These tumors have comparable character-
istics of low proliferative activity and indolent behav-
ior. The oncogenic mutations play a critical role in
the transmission of growth signals pathway and neo-
Type I pathway
Type II pathway
– Frequent BRSF/KRAS mutations
– Low cellular proliferation
– Gradual increase in CIN
– 5-year survival -55%
– Frequent p53 mutations
– High cellular proliferation
– High CIN
– Frequent HLA-G expression
– 5-year survival -55%
Ovarian surface
epithelium/inclusions
Conventional high-grade
serous carcinoma
Invasive MPSC or
low-grade serous
carcinoma
Serous cystadenoma
SBT or APST MPSC
Figure 1. Schematic representation of the proposed model of tumorigenesis pathways. Abbreviation: SBT, serous borderline tumor;
APST, atypical proliferative serous tumor; MPSC, micropapilary serous carcinoma (with permission from R.J. Kurman Am J Pathol
2004;164:1511-8).
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plastic transformation through the mitogen-activated
protein kinase (MAPK). Other study indicated that
mutations in either codon 599 of BRAF or codons 12
and 13 of KRAS counted for 86% in MPSC and 61%
in the serous borderline tumors.12,13 A study that ob-
served the adjacent epithelium from cystadenoma pre-
sumed as SBT precursor has showed lack of cytologi-
cal epithelial; however same mutations of BRAF and
KRAS occurred in the adjacent epithelial as in the
SBT (seven to eight SBT had either BRAF or KRAS
mutations and six of seven adjacent epithelium of cys-
tadenoma showed the same mutations). These muta-
tions appeared to occur very early in the development
of low-grade ovarian cancer.14
Mucinous tumors of ovaries without any associated
to either psedomyxoma peritonei (PMP) or metastatic
spread from the upper gastrointestinal tract are predomi-
nantly confined within the ovaries. Mucinous cancers
are often found well-differentiated with areas of border-
line and mucinous cystadenomas. The invasive growth
can be usually found as a focus in mucinous borderline
tumors (MBT).15 From molecular analysis, the KRAS
oncogene mutations reported existing mostly in the
first stage tumors in all subtypes but majorly in muci-
nous ovarian cancers.16,17 Such mutations were dis-
covered in the suggested early morphologic transition
of adjacent mucinous cystadenomas into MBT and
eventually mucinous carcinomas.18
Furthermore, endometriosis has been long associ-
ated as precursor of endometrioid and clear cell type
ovarian cancer. The cases are mostly found in pre-
maneopausal age and early stage cancer with possible
different mechanism of carcinogenesis for both sub-
types.19,20 Endometrioid type has a long history of
beta-catenin gene (CTNNB1) mutations involvement.
Alterations on CTNNB1 along with PTEN were ob-
served to a greater extent in endometrioid ovarian car-
cinoma and associated with endometriosis more often
than in tumors without endometriosis.21,22 A nearly
constant molecular mutations and microsatellite insta-
bility of CTNNB1 are present in borderline en-
dometrioid ovarian tumors, whereas PTEN and KRAS
mutations and microsatellite instability are less fre-
quent. It is suggesting that CTNNB1 mutations are
involved in the early event of low-grade endometrioid
ovarian carcinogenesis.23 As in clear cell type of ovar-
ian tumor, the molecular genetic changes were found
in several distinctive factors. Up-regulated HNF1B
(hepatocyte nuclear factor-1 beta) was found in al-
most 90-100% of clear cells specimens.24,25 Some of
the studies reported KRAS mutations (5-16%), mi-
crosatellite instability (13-50%), and at least 66% of
TGF-β RII mutations on clear cell type but the fre-
quency derived from limited cases.18 But in fact, clear
cell subtype do not share typical type I or type II
designated pathway group. This subtype tends to be
found in advanced stage although unlike type II tu-
mors it is more genetically stable. Microsatellite in-
stability of clear cell subtypes apply the same as in
endometrioid subtype confirming endometriosis in-
volvement as precursor.26
Figure 2. A, Invasive low grade micropapilary serous carcinoma
characterized by a micropapilary architecture and grade I nuclei.
B, High grade serous carcinoma with a solid growth patten and
grade 3 nuclei or grade C, An unusual case of a synchronous
high grade (H) and low grade (L) serous carcinoma. Antibody
against Rsf-1 was used to stain high grade serous carcinoma.
D, serous carcinoma with grade 2 nuclei (with permission from
R.J. Kurman Int J of Gynecol Pathol 2008; 27:151-60).
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In contrast, the tumors which are categorized as
having type II pathway of ovarian cancer are consid-
ered high grade at presentation. The high-grade serous
carcinoma, undifferentiated carcinoma, and malignant
mixed mesodermal tumors have tendency to feature
the same clinicopathological patterns. Designated type
II carcinomas are uncommonly associated with
morphologically recognizable precursor lesions.5,12
Higher Ki-67 nuclear labeling index in high-grade
serous carcinoma compared to low-grade serous car-
cinoma is presumably because of rapid transit from
inception as a microscopic carcinoma to a clinically
diagnosed neoplasm. Type II group evolves and me-
tastasizes aggressively. Precursor lesions are hardly
elucidated presumably due to the rapid transit.27 TP53
mutations are observed consistently in type II; at least
50-80% of advanced stage high grade serous carci-
noma showed p53 mutations and approximately 37%
is showed in stage I and stage II.28,32 Similar TP53
mutations are also demonstrated in malignant meso-
dermal tumors advising the same pathway of carcino-
genesis.33 In efforts to reveal the rapid transit of the
type II inception, the fallopian tubes derived from
prophylactic bilateral salpingooophorectomies on wo-
men with BRCA1/2 mutations were analyzed. Tubal
carcinoma was detected in both histologic evaluation
and immunostaining in women with BRCA1/2 posi-
tive. Genomic instability, TP53 mutations, and drama-
tically increased proliferation marked by increased
Ki-67 were observed in these early developments in
fallopian tubes but not in ovarian cortical inclusion
cyst. Genetic abnormalities were found in both fallo-
pian tube mucosal and ovarian tumors. The gene copy
abnormalities obtained from risk-reducing salpingec-
tomies which showed in situ epithelial lesions sug-
gested that the chromosomal instability is a very early
event in serous carcinoma. It hypothesized that the
early lesion of women with high risk of ovarian car-
cinoma in particular the high grade serous carcinoma
happened to be aroused from the epithelium of the
fimbriated end of fallopian tubes or involved the mu-
cosal fimbriated fallopian tubes. In total of 11 articles
of tubal involvement in serous ovarian cancer, 31
cases were observed over 51 cases of high risk pro-
phylactic bilateral salpingoophorectomies.34-39
Table 1. Summary of precursor, molecular genetic alteration, and clinical behavior of ovarian carcinoma subtypes
Ovarian carcinoma subtypes
High grade serous
carcinoma
Low grade serous
carcinoma
Mucinous
carcinoma
Endometrioid
carcinoma
Clear-cell
carcinoma
Presumable
precursor
lesion
Fallopian tube or
tubal metaplasia in
inclusions of ovarian
surface epithelium
Serous cystadenoma/
adenofibroma
Atypical proliferative
serous tumor (APST)
Non-invasive micro
papillary serous
carcinoma (MPSC) or
serous borderline
tumor (SBT)
Invasive MPSC
Mucinous cysta
denoma
Atypical proliferative
mucinous tumor
Intraepithelial carcino-
ma
Endometriosis
Endometrioid adeno-
fibroma
Atypical proliferative
endometrioid tumor
Intraepithelial carcino-
ma
Endometriosis clear
cell adenofibroma
Atypical proliferative 
clear cell tumor
Intraepithelial carcino-
ma
Molecular
protein altera-
tion
TP53 mutations
(50-80%)
Amplification and
overexpression of
HER2/neu gene and
 AKT2 gene (12-18%)
RB1 pathway
BRAF or KRAS
mutations (67%)
KRAS mutations
(>60%)
Lost of heterozygo-
city or mutations in
PTEN (20%)
CTNNB1 mutations
(16-54%)
KRAS mutations
(4-5%)
Up-regulated HNFB1
(90--100%)
TGF-β RII mutations
(60%)
Microsatellite instabil-
ity (13-50%)
KRAS mutations
(5-16%)
Proliferation High Low Intermediate Low Low
Genetic risk BRCA1/2 ? ? HNPCC ?
Clinical
behavior
Rapid and aggressive
growth
Majorly found at
advanced stage
G2/G3
Indolent and slow
progression
Majorly found at
early stage G1
Indolent and slow
progression
Majorly found at
early stage G1-G3
Indolent and slow
progression
Majorly found at
early stage G1-3
Indolent and slow
progression
Found at early and
advanced stages G3
Response rate
to chemo
therapy
80% 26-80% 15% ? 15%
5-year sur-
vival
30-38% 51.5% 71.4% 67.1% 50.8%
Prognosis Poor Favorable Favorable Favorable Intermediate
Abbreviation: TP53, tumor protein 53; HER2/neu, human epidermal growth factor 2; AKT2, protein kinase B-2; RB1, retinoblastoma tumor
suppressor; BRAF, v-raf murine sarcoma viral oncogene homologue; KRAS, Kirsten rat sarcoma viral oncogene homologue; CTNNB1, catenin
(cadherin-associated protein) beta 1; HNFB1, hepatocyte nuclear factor beta-1; TGF-β RII, transforming growth factor beta receptor 2; PTEN,
phosphatase and tensin homologue; BRCA1/2, breast cancer early-onset 1/2; HNPCC, heriditary nonpolyposis colon cancer; G, grade (Adapted
with permission from Editorial committee of Expert Rev Mol Med. 2008;10(22) and R.J. Kurman Am J Pathol 2004;164:1511-8).
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Different Approach of Treatment Based on
Suggested Designated Pathways of Ovarian
Cancer
Supported by the two pathways with their distinctive
attitudes, a new strategy or treatment approach of
ovarian cancers could be provided. Type I tumors
which are mostly confined in ovary appear mostly in
early stages. Optimal surgical staging and mass re-
moval followed by adjuvant chemotherapy have
shown benefits clinically for these stages.40,41 In ad-
dition to the confined state, type I tumors maintain to
show different alterations or mutations in mitogen-
activated protein kinase (MAPK) pathway. Conse-
quently the effort of treatment should be targeted on
the MAPK pathway. Inhibitor treatment and targeted
immunotherapy possibly can act as a strategy for type
I tumors therapy.12 As widely known, MAPK pathway
is important for signal transduction by coupling intra-
cellular responses to the binding growth factors and
cell surface which in turn responsible for cell prolif-
eration and differentiation. Some fundamental studies
towards MAPK pathway have been done both in vitro
and in vivo. A research of mutated KRAS oncogene
on more than 200 regulatory genes indicated that at
least 79 critical genes related to the application of
anchorage-independent proliferation and epithelial-
mesenchymal transition using MAPK and phospha-
tidylinositol 3-kinase (PI3K) pathways. Reversion to
the normal ovarian surface in rat model achieved by
blocking MAPK or partly induced by silencing of the
overexpressed transcriptional regulator Fra-1 by RNA
interference.42 MAPK phosphatase 1 (MKP-1) ac-
counts for extracellular signal-regulated kinase
(ERK1/2) deactivation is thought to be downregulated
on cancer cells which lead to ERK hyperactivity. Pro-
teosome inhibitor ZLLF-CHO or silencing ERK1/2
gene using RNA interference will hamper the cell’s
ability to proliferate.43 Gonadotrophin releasing hor-
mone-II (GnRH-II) effects on activation of p38
MAPK and ERK1/2. Activation of p38 by GnRH-II
plays a role in apoptosis through activation of activa-
tor protein-1. GnRH-II might possibly be a crucial
target for therapy given that the activation of ERK1/2
by GnRH-II is reversed by blocking phosphorylated
Elk-1, the downstream pathway.44,45
Beside MAPK pathway, there are some other tar-
gets of potential interest such as epidermal growth
factor receptor (ErbB) family. Erlotinib, cetuximab,
and gefitinib are drugs which inhibit overexpression
of ErbB. Clinical trial of erlotinib combine with the
standard chemotherapy of ovarian cancer is still on
going. A phase Ib clinical trial of erlotinib with do-
cetaxel/carboplatin showed more benefits as mainte-
nance therapy in particular.46 Cetuximab combined
with standard chemotherapy does not give additional
advantage on phase II trial in advanced stage patients;
no prolongation of progression free survival and as-
sociation with rash as hypersensitivity reactions in
majority patients.46,47 The gefitinib experience of
phase II study reported that the patients needed to be
screened for activating mutations in the epidermal
growth factor receptor (EGFR) in order to increase
the response rate to gefitinib on patients with recur-
rent ovarian or primary peritoneal carcinoma.48 Other
target therapy is vascular endothelial growth factor
(VEGF) which well-known inhibitor is bevacizumab.
Bevacizumab in combination with standard chemo-
therapy has demonstrated excellent efficacy for the
treatment of recurrent ovarian cancer. It is reported
to be well-tolerated in phase II trial by Gynecology
Oncology Group (GOG) as the second line or third
line treatment. Unfortunately the benefits have come
with a serious complication if bowel perforations
making a slower progression in clinical practice.49-51
Nevertheless, there are no data on early stage patients
with these drugs, possibly because the survival is
quite good with standard chemotherapy and chemo-
therapy is aiming majorly to advanced stages with
cases of chemoresistance.
The vast majority of ovarian cancers exhibit the
characteristics of those which are suitable to desig-
nated type II pathway; extremely aggressive and ad-
vanced stage at presentation. They are mainly high
grade serous carcinoma, account for 70% of all ovar-
ian carcinomas and are found almost 90% at stage III
or IV.7,52 Rapid transit accompanied by unidentifiable
precursor lesion hinders any efforts of early detection.
The early detection strategy might be useful for slow-
growing tumors but not for the type II tumors. A
meta-analysis showed that improving prognosis of ad-
vanced ovarian cancer has involved the optimal cyto-
reduction surgery; each 10% increase in maximal cy-
toreduction amplifies the median survival time for at
least 5.5%. Surgical techniques have evolved the con-
stitution of optimal cytoreduction. It has shifted from
less than 2 cm to less than 1.5 cm and finally to less
then 1 cm. Therefore, the proposed strategy of screen-
ing type II pathway is detection of minimal ovarian
carcinoma define as microscopic to 1 cm lesions which
could be detected ultimately by biomarkers because
of the lack of recognizable precursors. Treatment of
type II pathway depends on maximal primary cytore-
duction like the type I pathway. Hence consistent re-
ferral of patients with apparent advanced ovarian can-
cer to gynecology oncology centers for primary sur-
gery might be the best approach currently available
to improve overall survival.18,53
Besides the importance of optimal cytoreduction to
reach minimal size of tumor mass, two important is-
sues that also deprive attention are genetic risk and
protein mutations affected, TP53. BRCA1 and BRCA2,
carried by patients with hereditary breast/ovarian can-
cer, are mainly high-grade serous carcinoma. The mu-
tations could happen in one allele of either BRCA1
or BRCA2. BRCA1/2 germline mutations are exclu-
sively existed in high-grade serous carcinoma, which
suggested having designated type II pathway.53,54
Granting only 16-20% of all histology subtypes of
ovarian cancer associated with BRCA1/2 mutations,
some studies reported that the BRCA1/2-associated
group had a longer recurrence-free and longer overall
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survival compare to non-associated group. It also
showed that BRCA1 mRNA levels were related to the
overall survival in sporadic ovarian cancers even
though the mechanisms are not clear yet.55-58 The rou-
tine screening of BRCA1/2 among positive hereditary
breast-ovarian cancer failed to show benefit in in-
creasing overall survival. Despite of reduction of
breast and gynecological cancer incidence among car-
riers after mastectomy and prophylactic gynecological
surgery including bi- or unilateral oophorectomy, a
systematic review of research reported flaws in
screening efficiency of familial breast-ovarian malig-
nancy conducted in 1996-2005.59 Developing strategy
for BRCA1/2 as critical predictor for ovarian cancer
is considerable because mainly the BRCA1/2 associ-
ated ovarian cancers manifest as high grade serous
subtype. Regardless the screening which could possi-
bly only be accounted for one fifth of all incidences,
improvement of BRCA1/2 status detection and further
classification is necessary to be applicable in clinical
daily use.
As the protein affected, mutations in TP53 could
reach between 50-80% of all invasive ovarian can-
cers.29,32,60 TP53 is the gene mostly responsible for
cell cycle regulation including apoptosis and resolving
DNA damage. Gene mutations contribute to the loss
of cell regulation and lead to an excessive cell pro-
liferation and dysfunction. The type of mutation is
mainly missense mutations that allow a genetic
change involving the substitution of one base in the
DNA for another which in turn change one amino
acid in a polypeptide for another.32 Mutation in TP53
appears to develop very early in the genesis of type
II neoplasia in the fimbriated part of fallopian tubes
of BRCA-positive patients.39 Regarding correlation of
TP53 with the early detection, there have to be a bet-
ter of identification other than immunohisto-chemistry
staining in order to offer useful method of screening.
The correlation of the mutations to the prognosis or
chemotherapy sensitivity remains unclear. Some data
suggest that the loss of function of p53 tend to have
more favorable clinical response to chemotherapy. It
was supporting a model whereby p53 mediated cell-
cycle-arrest/DNA repair served as a barrier to optimal
chemotherapy.61-63 Other data implicate that mutated
p53 are more responsive to taxane-based or taxane-
platinum-based chemotherapy than platinum standard
chemotherapy which addressed chemoresistancy than
chemosensitivity.64,65 It is also crucial to further in-
vestigate TP53 mutations since they are inherited dur-
ing cancer evolution and contribute to the transformed
state. New technologies such is BEAM-ing which de-
tect small amounts of mutations or highly sensitive
mass spectrometry or even specific capture enzyme-
linked immunosorbent assay (ELISA) could be util-
ized to detect expression products of the mutant
marker genes.18,66
CONCLUSION
A new model of ovarian tumorigenesis is developed
based on rigorous studies of pathology and molecular
genetics. Two proposed pathways are designated type
I and type II. Type I tumors are characterized by in-
dolent behavior and slow progression while type II
have the opposite characters, rapid and aggressive
growth. Type I tumors include low-grade serous,
mucinous; clear cell and endometrioid ovarian carci-
noma while high-grade serous subtypes are dominant
in type II tumors. Type I tumors are known previously
through precursor lesions which develop in stepwise
manner. It is recommended that low grade serous
ovarian cancers are developed from adenofibroma or
atypical proliferative serous tumor into non invasive
MPSC then finally into invasive MPSC. The process
could take almost 20 years to be invasive. Regarding
therapy, optimal surgery prior to adjuvant chemother-
apy is still the best strategy to type I pathway which
is usually confined in the ovary. Mutations of MAPK
pathways such as KRAS, BRAF, PTEN, and
CTNNB1 are expressed mostly in type I group along
with the low response to platinum-based chemother-
apy. Efforts to strengthen the chemotherapy effect by
looking at MAPK pathway as target are put forward
in the future directions. Some inhibitor treatment and
targeted immunotherapy should also develop toward
not only advanced stages but early stages with low
response.
The quest into finding the rapid transient pre-lesion
which is presented the high grade serous ovarian can-
cer comes across the findings of presumably pre-le-
sion in epithelial or mucosal of fimbriated fallopian
tubes among BRCA1/2-associated hereditary breast/
ovarian cancer patients. Meanwhile, the type II tu-
mors best approach should possibly be shifted from
stage I detection into detection of minimal ovarian
carcinoma which only be recognized by biomarkers.
Consistent referral to gynecology oncology center
would give valued in term of optimal surgical cytore-
duction. Type II tumors also showed more p53 mu-
tations and more associations with hereditary
BRCA1/2 syndrome with problem of high recurrences
after first chemotherapy. In spite of the roles of p53
mutations remain more explanations in clinical prac-
tice, TP53 could be correlated to chemo-resistance to-
ward platinum based therapy and sensitivity to taxane
therapy. Mutations of TP53, found coherently in
fimbriated fallopian tubes of BRCA1/2 hereditary-
associated ovarian cancer, could possibly act as a
starting point toward type II ovarian cancer screening
while improving the BRCA1/2 status screening and
bilateral salpingo-oophorectomies could be retained
as screening strategy in the breast/ovarian cancer he-
reditary group.
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